| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polyenes | 14 | 2008 | 35 | 2.090 |
Why?
|
| Neoplasms | 32 | 2023 | 15193 | 1.700 |
Why?
|
| Antineoplastic Agents, Immunological | 8 | 2023 | 1249 | 1.560 |
Why?
|
| Metformin | 12 | 2021 | 378 | 1.560 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 3 | 2019 | 68 | 1.400 |
Why?
|
| Emergency Service, Hospital | 15 | 2022 | 1148 | 1.400 |
Why?
|
| Trastuzumab | 2 | 2021 | 696 | 1.240 |
Why?
|
| Pulmonary Embolism | 3 | 2020 | 329 | 1.240 |
Why?
|
| Farnesyltranstransferase | 7 | 2009 | 122 | 1.150 |
Why?
|
| Head and Neck Neoplasms | 11 | 2023 | 3976 | 1.130 |
Why?
|
| Venous Thromboembolism | 3 | 2020 | 335 | 1.120 |
Why?
|
| Enzyme Inhibitors | 11 | 2009 | 1879 | 1.060 |
Why?
|
| Breast Neoplasms | 18 | 2023 | 15694 | 1.040 |
Why?
|
| Thyroid Neoplasms | 10 | 2007 | 1866 | 0.970 |
Why?
|
| Cardiotoxicity | 3 | 2023 | 155 | 0.970 |
Why?
|
| Polyunsaturated Alkamides | 14 | 2008 | 35 | 0.930 |
Why?
|
| Anthracyclines | 2 | 2021 | 331 | 0.860 |
Why?
|
| Antineoplastic Agents | 22 | 2023 | 14289 | 0.860 |
Why?
|
| Peptide Hydrolases | 6 | 2014 | 256 | 0.830 |
Why?
|
| Myocarditis | 1 | 2023 | 190 | 0.800 |
Why?
|
| Immunotherapy | 7 | 2023 | 3341 | 0.800 |
Why?
|
| Hypoglycemic Agents | 6 | 2019 | 586 | 0.790 |
Why?
|
| Craniocerebral Trauma | 1 | 2022 | 130 | 0.770 |
Why?
|
| Magnesium Deficiency | 1 | 2020 | 21 | 0.770 |
Why?
|
| Humans | 138 | 2023 | 261506 | 0.750 |
Why?
|
| Paclitaxel | 9 | 2020 | 1996 | 0.720 |
Why?
|
| Renal Tubular Transport, Inborn Errors | 1 | 2019 | 11 | 0.700 |
Why?
|
| Thiazolidinediones | 4 | 2012 | 148 | 0.690 |
Why?
|
| Hypercalciuria | 1 | 2019 | 14 | 0.690 |
Why?
|
| Nephrocalcinosis | 1 | 2019 | 17 | 0.690 |
Why?
|
| Multiprotein Complexes | 5 | 2012 | 395 | 0.690 |
Why?
|
| Fentanyl | 1 | 2020 | 148 | 0.680 |
Why?
|
| Tracheal Neoplasms | 1 | 2019 | 42 | 0.680 |
Why?
|
| Diabetic Ketoacidosis | 2 | 2018 | 136 | 0.680 |
Why?
|
| Everolimus | 4 | 2019 | 415 | 0.670 |
Why?
|
| Blood Coagulation Tests | 1 | 2019 | 87 | 0.670 |
Why?
|
| Middle Aged | 57 | 2022 | 86204 | 0.660 |
Why?
|
| Plasmacytoma | 1 | 2019 | 111 | 0.650 |
Why?
|
| Cancer Care Facilities | 4 | 2018 | 884 | 0.640 |
Why?
|
| Receptor, ErbB-2 | 6 | 2021 | 2518 | 0.630 |
Why?
|
| Aged | 47 | 2023 | 70117 | 0.630 |
Why?
|
| Prognosis | 20 | 2023 | 21713 | 0.630 |
Why?
|
| Ubiquitin-Protein Ligases | 8 | 2015 | 854 | 0.610 |
Why?
|
| Cancer Survivors | 2 | 2021 | 650 | 0.610 |
Why?
|
| Calcium Gluconate | 1 | 2017 | 7 | 0.600 |
Why?
|
| Esophageal Neoplasms | 9 | 2023 | 3168 | 0.590 |
Why?
|
| Hospice and Palliative Care Nursing | 3 | 2022 | 56 | 0.590 |
Why?
|
| Hypoparathyroidism | 1 | 2017 | 49 | 0.580 |
Why?
|
| Female | 75 | 2023 | 141928 | 0.580 |
Why?
|
| Airway Obstruction | 1 | 2019 | 261 | 0.560 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2016 | 49 | 0.560 |
Why?
|
| Apoptosis | 16 | 2020 | 7591 | 0.550 |
Why?
|
| Hypertension | 2 | 2021 | 1503 | 0.550 |
Why?
|
| Alkyl and Aryl Transferases | 4 | 2005 | 87 | 0.540 |
Why?
|
| Proto-Oncogene Proteins c-akt | 7 | 2020 | 2054 | 0.540 |
Why?
|
| Carboplatin | 5 | 2020 | 823 | 0.540 |
Why?
|
| Carcinoma | 7 | 2015 | 2578 | 0.530 |
Why?
|
| Cushing Syndrome | 1 | 2016 | 70 | 0.530 |
Why?
|
| Cancer Pain | 1 | 2020 | 312 | 0.520 |
Why?
|
| Obesity | 5 | 2019 | 2884 | 0.520 |
Why?
|
| Troponin I | 1 | 2016 | 127 | 0.520 |
Why?
|
| Signal Transduction | 20 | 2021 | 11965 | 0.520 |
Why?
|
| SEER Program | 1 | 2018 | 1000 | 0.510 |
Why?
|
| Cell Line, Tumor | 35 | 2023 | 14551 | 0.510 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2019 | 486 | 0.500 |
Why?
|
| Antineoplastic Agents, Phytogenic | 4 | 2007 | 852 | 0.500 |
Why?
|
| Autophagy | 3 | 2014 | 927 | 0.500 |
Why?
|
| Pancreatitis | 1 | 2017 | 267 | 0.500 |
Why?
|
| Gene Regulatory Networks | 2 | 2017 | 677 | 0.500 |
Why?
|
| Shock, Septic | 1 | 2016 | 181 | 0.480 |
Why?
|
| Male | 60 | 2022 | 123000 | 0.470 |
Why?
|
| Survivors | 1 | 2019 | 1031 | 0.470 |
Why?
|
| Cell Proliferation | 16 | 2020 | 7226 | 0.470 |
Why?
|
| Hyperglycemia | 2 | 2016 | 333 | 0.460 |
Why?
|
| Neurosurgical Procedures | 1 | 2018 | 609 | 0.450 |
Why?
|
| Neoadjuvant Therapy | 5 | 2022 | 4975 | 0.450 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 598 | 0.450 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2015 | 460 | 0.450 |
Why?
|
| Androstadienes | 2 | 2019 | 165 | 0.450 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 2012 | 31 | 0.440 |
Why?
|
| Osteitis Deformans | 1 | 2012 | 34 | 0.430 |
Why?
|
| Reactive Oxygen Species | 4 | 2021 | 987 | 0.430 |
Why?
|
| Alcoholism | 1 | 2015 | 285 | 0.430 |
Why?
|
| Chemoradiotherapy | 2 | 2020 | 1946 | 0.430 |
Why?
|
| Insulin | 4 | 2012 | 1454 | 0.420 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2015 | 810 | 0.420 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2019 | 3890 | 0.420 |
Why?
|
| Body Composition | 1 | 2015 | 595 | 0.410 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2021 | 8873 | 0.410 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2018 | 1216 | 0.410 |
Why?
|
| Sepsis | 4 | 2023 | 652 | 0.400 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2012 | 179 | 0.400 |
Why?
|
| 14-3-3 Proteins | 4 | 2015 | 143 | 0.400 |
Why?
|
| Taxoids | 1 | 2015 | 967 | 0.400 |
Why?
|
| Adult | 31 | 2021 | 77950 | 0.390 |
Why?
|
| Stomatitis | 2 | 2023 | 183 | 0.390 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2011 | 82 | 0.380 |
Why?
|
| Lymphoma | 2 | 2019 | 1467 | 0.380 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2012 | 402 | 0.380 |
Why?
|
| Ubiquitination | 14 | 2015 | 575 | 0.380 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 1371 | 0.370 |
Why?
|
| Opioid-Related Disorders | 1 | 2015 | 394 | 0.370 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2015 | 425 | 0.370 |
Why?
|
| Mice, Nude | 17 | 2017 | 4307 | 0.370 |
Why?
|
| Biomarkers, Tumor | 10 | 2022 | 10331 | 0.360 |
Why?
|
| Mucositis | 2 | 2023 | 148 | 0.360 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 3 | 2016 | 280 | 0.360 |
Why?
|
| Leukemia | 1 | 2019 | 1635 | 0.360 |
Why?
|
| Sirolimus | 1 | 2014 | 814 | 0.360 |
Why?
|
| Mice | 36 | 2023 | 34495 | 0.350 |
Why?
|
| DNA Damage | 7 | 2015 | 1954 | 0.350 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2020 | 15862 | 0.350 |
Why?
|
| Postmenopause | 3 | 2019 | 378 | 0.350 |
Why?
|
| Saliva | 2 | 2022 | 231 | 0.350 |
Why?
|
| DNA, Catalytic | 1 | 2009 | 4 | 0.350 |
Why?
|
| Animals | 47 | 2023 | 59536 | 0.340 |
Why?
|
| Emergencies | 2 | 2023 | 202 | 0.340 |
Why?
|
| Adaptor Proteins, Signal Transducing | 5 | 2015 | 1439 | 0.340 |
Why?
|
| Glycolysis | 3 | 2022 | 519 | 0.340 |
Why?
|
| COP9 Signalosome Complex | 9 | 2015 | 72 | 0.340 |
Why?
|
| Thrombosis | 2 | 2017 | 781 | 0.330 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2008 | 55 | 0.330 |
Why?
|
| Retrospective Studies | 21 | 2022 | 37905 | 0.330 |
Why?
|
| Antibodies, Monoclonal | 4 | 2019 | 4367 | 0.330 |
Why?
|
| Computational Biology | 1 | 2015 | 1271 | 0.330 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2018 | 1215 | 0.330 |
Why?
|
| Lymph Nodes | 1 | 2019 | 2967 | 0.330 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2021 | 1362 | 0.320 |
Why?
|
| Bone Neoplasms | 3 | 2020 | 2576 | 0.320 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 2195 | 0.320 |
Why?
|
| ras Proteins | 1 | 2012 | 770 | 0.320 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 1870 | 0.310 |
Why?
|
| Receptors, Estrogen | 2 | 2019 | 2086 | 0.310 |
Why?
|
| Ovarian Neoplasms | 4 | 2020 | 4638 | 0.310 |
Why?
|
| Exosomes | 2 | 2022 | 253 | 0.300 |
Why?
|
| Tumor Suppressor Protein p53 | 7 | 2013 | 3552 | 0.300 |
Why?
|
| Glioblastoma | 1 | 2018 | 1797 | 0.300 |
Why?
|
| Computed Tomography Angiography | 2 | 2019 | 234 | 0.300 |
Why?
|
| ROC Curve | 4 | 2019 | 1183 | 0.300 |
Why?
|
| Translocation, Genetic | 1 | 2012 | 1245 | 0.290 |
Why?
|
| Transcriptome | 2 | 2015 | 1859 | 0.280 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2009 | 323 | 0.280 |
Why?
|
| TOR Serine-Threonine Kinases | 5 | 2020 | 1546 | 0.270 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2022 | 1048 | 0.270 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 2005 | 24 | 0.270 |
Why?
|
| Smoking | 1 | 2015 | 2440 | 0.270 |
Why?
|
| Diagnosis, Differential | 5 | 2019 | 4744 | 0.270 |
Why?
|
| Lung Neoplasms | 5 | 2020 | 11538 | 0.270 |
Why?
|
| Tachycardia | 2 | 2023 | 70 | 0.260 |
Why?
|
| Transplantation, Heterologous | 7 | 2010 | 1082 | 0.260 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 4988 | 0.260 |
Why?
|
| Thrombocytopenia | 1 | 2010 | 846 | 0.260 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2020 | 4938 | 0.250 |
Why?
|
| HCT116 Cells | 7 | 2021 | 348 | 0.250 |
Why?
|
| Survival Rate | 7 | 2019 | 12221 | 0.240 |
Why?
|
| Delirium | 2 | 2017 | 207 | 0.240 |
Why?
|
| Adipokines | 2 | 2014 | 96 | 0.240 |
Why?
|
| Pheochromocytoma | 2 | 2022 | 281 | 0.240 |
Why?
|
| Tumor Burden | 7 | 2022 | 1987 | 0.240 |
Why?
|
| Overweight | 3 | 2019 | 484 | 0.240 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2015 | 2359 | 0.240 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2018 | 5437 | 0.230 |
Why?
|
| Disease-Free Survival | 6 | 2021 | 10001 | 0.230 |
Why?
|
| Caspases | 3 | 2003 | 661 | 0.230 |
Why?
|
| Acupuncture | 2 | 2020 | 22 | 0.230 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 2488 | 0.230 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p57 | 2 | 2013 | 64 | 0.220 |
Why?
|
| Palliative Care | 4 | 2022 | 2037 | 0.220 |
Why?
|
| Postoperative Complications | 1 | 2018 | 5542 | 0.220 |
Why?
|
| Aged, 80 and over | 12 | 2021 | 29902 | 0.220 |
Why?
|
| Insulin, Long-Acting | 2 | 2012 | 18 | 0.220 |
Why?
|
| Prevalence | 7 | 2022 | 3260 | 0.220 |
Why?
|
| Insulin Glargine | 2 | 2012 | 20 | 0.220 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2015 | 287 | 0.220 |
Why?
|
| Pain | 3 | 2022 | 1658 | 0.220 |
Why?
|
| Acute Disease | 3 | 2017 | 2422 | 0.210 |
Why?
|
| Hot Flashes | 2 | 2020 | 37 | 0.210 |
Why?
|
| STAT3 Transcription Factor | 3 | 2021 | 1121 | 0.210 |
Why?
|
| RNA, Small Interfering | 6 | 2015 | 2216 | 0.210 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2022 | 489 | 0.210 |
Why?
|
| RNA, Small Untranslated | 1 | 2022 | 29 | 0.210 |
Why?
|
| Acupuncture Therapy | 2 | 2020 | 89 | 0.210 |
Why?
|
| Cell Hypoxia | 3 | 2009 | 328 | 0.210 |
Why?
|
| Cytochrome c Group | 1 | 2001 | 71 | 0.210 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2012 | 2796 | 0.210 |
Why?
|
| Intensive Care Units | 3 | 2016 | 717 | 0.200 |
Why?
|
| MicroRNAs | 3 | 2023 | 2947 | 0.200 |
Why?
|
| Cisplatin | 5 | 2020 | 2432 | 0.200 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2023 | 160 | 0.200 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 14889 | 0.200 |
Why?
|
| Febrile Neutropenia | 1 | 2021 | 65 | 0.200 |
Why?
|
| Young Adult | 11 | 2021 | 21445 | 0.200 |
Why?
|
| Cystine | 1 | 2021 | 34 | 0.200 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 4849 | 0.200 |
Why?
|
| Cyclins | 1 | 2003 | 456 | 0.200 |
Why?
|
| Exonucleases | 2 | 2011 | 51 | 0.200 |
Why?
|
| alpha7 Nicotinic Acetylcholine Receptor | 1 | 2021 | 57 | 0.190 |
Why?
|
| Carcinogenesis | 3 | 2021 | 1026 | 0.190 |
Why?
|
| Pancreatic Neoplasms | 5 | 2012 | 5061 | 0.190 |
Why?
|
| Drug Synergism | 4 | 2020 | 1313 | 0.190 |
Why?
|
| Fatal Outcome | 3 | 2012 | 829 | 0.190 |
Why?
|
| Neoplasm Transplantation | 5 | 2016 | 1519 | 0.190 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2019 | 755 | 0.190 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2019 | 182 | 0.190 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2021 | 123 | 0.190 |
Why?
|
| Transfection | 8 | 2015 | 2944 | 0.190 |
Why?
|
| Extracellular Vesicles | 1 | 2022 | 135 | 0.190 |
Why?
|
| Adolescent | 10 | 2020 | 31252 | 0.180 |
Why?
|
| Aurora Kinases | 5 | 2012 | 189 | 0.180 |
Why?
|
| Mesenchymoma | 1 | 2000 | 14 | 0.180 |
Why?
|
| Osteomalacia | 1 | 2000 | 36 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2014 | 1493 | 0.180 |
Why?
|
| Administration, Intranasal | 1 | 2020 | 190 | 0.180 |
Why?
|
| Neoplasm Grading | 3 | 2022 | 1742 | 0.180 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 265 | 0.180 |
Why?
|
| Exoribonucleases | 3 | 2015 | 42 | 0.180 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2017 | 726 | 0.180 |
Why?
|
| Hospitalization | 4 | 2018 | 2083 | 0.180 |
Why?
|
| Neoplasm Staging | 6 | 2023 | 13658 | 0.180 |
Why?
|
| Melanoma | 1 | 2017 | 5317 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 3 | 2012 | 507 | 0.180 |
Why?
|
| Quinazolines | 3 | 2010 | 923 | 0.180 |
Why?
|
| Survival Analysis | 5 | 2020 | 9180 | 0.170 |
Why?
|
| N-Terminal Acetyltransferase C | 1 | 2019 | 3 | 0.170 |
Why?
|
| Caspase 3 | 4 | 2006 | 471 | 0.170 |
Why?
|
| Case-Control Studies | 4 | 2020 | 6100 | 0.170 |
Why?
|
| Time Factors | 9 | 2020 | 12926 | 0.170 |
Why?
|
| Osteoradionecrosis | 1 | 2020 | 123 | 0.170 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 249 | 0.170 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2016 | 1533 | 0.170 |
Why?
|
| Prospective Studies | 8 | 2022 | 12873 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 2 | 2009 | 45 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2018 | 6207 | 0.170 |
Why?
|
| Phosphates | 1 | 2000 | 187 | 0.170 |
Why?
|
| Treatment Outcome | 9 | 2020 | 32848 | 0.170 |
Why?
|
| Neoplasms, Experimental | 2 | 2020 | 750 | 0.170 |
Why?
|
| Proteolysis | 3 | 2015 | 370 | 0.170 |
Why?
|
| Metastasectomy | 1 | 2020 | 200 | 0.160 |
Why?
|
| Analgesics | 1 | 2021 | 390 | 0.160 |
Why?
|
| Aurora Kinase B | 4 | 2012 | 68 | 0.160 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 2 | 2010 | 57 | 0.160 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2021 | 5178 | 0.160 |
Why?
|
| Colonic Neoplasms | 3 | 2021 | 1390 | 0.160 |
Why?
|
| Epirubicin | 1 | 2017 | 157 | 0.150 |
Why?
|
| Incidence | 5 | 2020 | 5673 | 0.150 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 2018 | 236 | 0.150 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2008 | 252 | 0.150 |
Why?
|
| Ergocalciferols | 1 | 2017 | 12 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2010 | 4757 | 0.150 |
Why?
|
| Magnesium Sulfate | 1 | 2017 | 39 | 0.150 |
Why?
|
| Morbidity | 1 | 2018 | 397 | 0.150 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2017 | 62 | 0.150 |
Why?
|
| Mice, Transgenic | 5 | 2021 | 4143 | 0.150 |
Why?
|
| Neoplasm Proteins | 2 | 2021 | 3230 | 0.140 |
Why?
|
| Cancer Vaccines | 1 | 2022 | 697 | 0.140 |
Why?
|
| Hypocalcemia | 1 | 2017 | 59 | 0.140 |
Why?
|
| Advance Directives | 1 | 2017 | 88 | 0.140 |
Why?
|
| Janus Kinase 2 | 1 | 2021 | 679 | 0.140 |
Why?
|
| Apolipoproteins B | 1 | 1996 | 106 | 0.140 |
Why?
|
| Patient Admission | 1 | 2018 | 220 | 0.140 |
Why?
|
| Ubiquitins | 1 | 1996 | 86 | 0.140 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2018 | 4549 | 0.140 |
Why?
|
| Phosphorylation | 8 | 2015 | 4804 | 0.140 |
Why?
|
| Immunoblotting | 4 | 2015 | 886 | 0.140 |
Why?
|
| Hypertriglyceridemia | 1 | 2017 | 104 | 0.140 |
Why?
|
| Emergency Treatment | 1 | 2017 | 105 | 0.140 |
Why?
|
| Xenograft Model Antitumor Assays | 8 | 2020 | 3821 | 0.140 |
Why?
|
| Heart Neoplasms | 1 | 2018 | 214 | 0.140 |
Why?
|
| Neovascularization, Pathologic | 2 | 2015 | 1547 | 0.140 |
Why?
|
| Dyspnea | 1 | 2019 | 416 | 0.140 |
Why?
|
| Vitamins | 1 | 2017 | 157 | 0.140 |
Why?
|
| Hospital Mortality | 3 | 2018 | 1274 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2018 | 5539 | 0.140 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2016 | 113 | 0.140 |
Why?
|
| Hemangiosarcoma | 1 | 2018 | 234 | 0.140 |
Why?
|
| Hypokalemia | 1 | 2016 | 55 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 2403 | 0.140 |
Why?
|
| Carbon Radioisotopes | 1 | 2015 | 116 | 0.130 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2018 | 565 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 5 | 2015 | 2314 | 0.130 |
Why?
|
| Multienzyme Complexes | 1 | 1996 | 213 | 0.130 |
Why?
|
| Gene Amplification | 1 | 2018 | 731 | 0.130 |
Why?
|
| Up-Regulation | 6 | 2018 | 2450 | 0.130 |
Why?
|
| Insurance Coverage | 1 | 2018 | 256 | 0.130 |
Why?
|
| Cysteine Endopeptidases | 1 | 1996 | 251 | 0.130 |
Why?
|
| Drug Therapy, Combination | 3 | 2019 | 2315 | 0.130 |
Why?
|
| Pneumonectomy | 1 | 2020 | 831 | 0.130 |
Why?
|
| Lymphatic Metastasis | 3 | 2023 | 4844 | 0.130 |
Why?
|
| Anticoagulants | 2 | 2019 | 787 | 0.130 |
Why?
|
| Prostatic Neoplasms | 1 | 2012 | 5767 | 0.130 |
Why?
|
| Interleukin-1beta | 1 | 2016 | 300 | 0.130 |
Why?
|
| Carcinoid Tumor | 2 | 2008 | 280 | 0.130 |
Why?
|
| Viruses | 1 | 2016 | 159 | 0.130 |
Why?
|
| Proteasome Endopeptidase Complex | 3 | 2011 | 589 | 0.130 |
Why?
|
| Viral Load | 1 | 2017 | 493 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 6 | 2004 | 5395 | 0.130 |
Why?
|
| Genetic Therapy | 2 | 2016 | 1616 | 0.130 |
Why?
|
| Atherosclerosis | 1 | 2023 | 935 | 0.130 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2019 | 363 | 0.130 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2015 | 142 | 0.130 |
Why?
|
| Hormone Replacement Therapy | 1 | 2017 | 205 | 0.130 |
Why?
|
| Radiopharmaceuticals | 2 | 2022 | 1301 | 0.130 |
Why?
|
| Neuralgia | 1 | 2018 | 251 | 0.130 |
Why?
|
| Inflammasomes | 1 | 2016 | 161 | 0.120 |
Why?
|
| Breast | 2 | 2018 | 1344 | 0.120 |
Why?
|
| Spinal Neoplasms | 1 | 2000 | 631 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2015 | 259 | 0.120 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2014 | 29 | 0.120 |
Why?
|
| RNA, Viral | 1 | 2017 | 671 | 0.120 |
Why?
|
| Protein Kinases | 2 | 2009 | 874 | 0.120 |
Why?
|
| Risk Factors | 6 | 2023 | 17523 | 0.120 |
Why?
|
| p21-Activated Kinases | 1 | 2014 | 122 | 0.120 |
Why?
|
| Pyruvic Acid | 1 | 2015 | 133 | 0.120 |
Why?
|
| Microbiota | 1 | 2020 | 547 | 0.120 |
Why?
|
| Calcium-Binding Proteins | 1 | 2016 | 545 | 0.120 |
Why?
|
| Counseling | 1 | 2016 | 381 | 0.120 |
Why?
|
| Fibroblast Growth Factors | 2 | 2013 | 257 | 0.120 |
Why?
|
| Adenocarcinoma | 4 | 2014 | 7789 | 0.120 |
Why?
|
| Radiology | 1 | 2019 | 434 | 0.120 |
Why?
|
| Ipilimumab | 1 | 2018 | 710 | 0.120 |
Why?
|
| Osteosarcoma | 1 | 2020 | 929 | 0.110 |
Why?
|
| Emergency Medical Services | 1 | 2018 | 429 | 0.110 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2015 | 803 | 0.110 |
Why?
|
| Cohort Studies | 7 | 2022 | 9244 | 0.110 |
Why?
|
| Blotting, Western | 8 | 2015 | 3536 | 0.110 |
Why?
|
| Virus Diseases | 1 | 2017 | 398 | 0.110 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 328 | 0.110 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 2864 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2019 | 1146 | 0.110 |
Why?
|
| Life Style | 1 | 2016 | 612 | 0.110 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2015 | 223 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 2018 | 899 | 0.110 |
Why?
|
| Insulin Aspart | 1 | 2012 | 6 | 0.110 |
Why?
|
| Oxygen Consumption | 1 | 2014 | 401 | 0.110 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2015 | 534 | 0.110 |
Why?
|
| Mutation | 1 | 2012 | 15179 | 0.110 |
Why?
|
| Patient Compliance | 1 | 2016 | 667 | 0.110 |
Why?
|
| Triage | 1 | 2014 | 252 | 0.110 |
Why?
|
| Genetic Markers | 1 | 2015 | 974 | 0.110 |
Why?
|
| Adipocytes | 1 | 2014 | 305 | 0.110 |
Why?
|
| C-Peptide | 1 | 2012 | 107 | 0.110 |
Why?
|
| HSP70 Heat-Shock Proteins | 2 | 2003 | 161 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2015 | 419 | 0.110 |
Why?
|
| F-Box Proteins | 1 | 2012 | 96 | 0.100 |
Why?
|
| Oxazoles | 1 | 2012 | 60 | 0.100 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 1 | 2012 | 60 | 0.100 |
Why?
|
| United States | 5 | 2022 | 15433 | 0.100 |
Why?
|
| Testicular Neoplasms | 1 | 2016 | 529 | 0.100 |
Why?
|
| Mastectomy | 1 | 2018 | 1534 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2015 | 2027 | 0.100 |
Why?
|
| Cullin Proteins | 1 | 2011 | 41 | 0.100 |
Why?
|
| Hydroxyurea | 1 | 2012 | 204 | 0.100 |
Why?
|
| Stomach Neoplasms | 2 | 2014 | 2278 | 0.100 |
Why?
|
| Weight Loss | 1 | 2016 | 627 | 0.100 |
Why?
|
| beta Catenin | 1 | 2015 | 688 | 0.100 |
Why?
|
| Liver Neoplasms | 3 | 2015 | 4557 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 6009 | 0.100 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2013 | 193 | 0.100 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2012 | 71 | 0.100 |
Why?
|
| Daunorubicin | 1 | 2012 | 301 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2018 | 3251 | 0.100 |
Why?
|
| Heterografts | 3 | 2021 | 733 | 0.100 |
Why?
|
| Immunohistochemistry | 5 | 2015 | 7548 | 0.100 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2012 | 134 | 0.100 |
Why?
|
| 4-Butyrolactone | 1 | 2010 | 8 | 0.100 |
Why?
|
| Receptors, Androgen | 1 | 2017 | 878 | 0.100 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2002 | 548 | 0.100 |
Why?
|
| Fatty Acid Synthases | 1 | 2010 | 24 | 0.100 |
Why?
|
| Aplysia | 3 | 1990 | 14 | 0.100 |
Why?
|
| Heart | 1 | 2017 | 1223 | 0.100 |
Why?
|
| Metabolic Syndrome | 1 | 2014 | 353 | 0.100 |
Why?
|
| Esophagogastric Junction | 1 | 2014 | 543 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2018 | 830 | 0.090 |
Why?
|
| Circadian Rhythm | 3 | 1990 | 330 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2022 | 7551 | 0.090 |
Why?
|
| Cysts | 1 | 2012 | 197 | 0.090 |
Why?
|
| Membrane Proteins | 2 | 2019 | 2819 | 0.090 |
Why?
|
| Cell Cycle Proteins | 2 | 2012 | 2045 | 0.090 |
Why?
|
| Extremities | 1 | 2012 | 303 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2016 | 1678 | 0.090 |
Why?
|
| Doxorubicin | 2 | 2012 | 3005 | 0.090 |
Why?
|
| Organophosphates | 1 | 2010 | 41 | 0.090 |
Why?
|
| Diabetes Complications | 1 | 2012 | 305 | 0.090 |
Why?
|
| Haploinsufficiency | 1 | 2011 | 294 | 0.090 |
Why?
|
| Inflammation | 2 | 2023 | 2522 | 0.090 |
Why?
|
| Phenotype | 3 | 2016 | 6295 | 0.090 |
Why?
|
| Cell Survival | 4 | 2015 | 3045 | 0.090 |
Why?
|
| Mammals | 1 | 2011 | 361 | 0.090 |
Why?
|
| Death | 1 | 2020 | 119 | 0.090 |
Why?
|
| Medicine, Chinese Traditional | 2 | 2020 | 30 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 7702 | 0.090 |
Why?
|
| Burkitt Lymphoma | 1 | 2012 | 335 | 0.090 |
Why?
|
| Energy Metabolism | 1 | 2015 | 992 | 0.090 |
Why?
|
| Protein Binding | 5 | 2015 | 3438 | 0.090 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2009 | 43 | 0.080 |
Why?
|
| HEK293 Cells | 4 | 2015 | 1489 | 0.080 |
Why?
|
| Exercise | 1 | 2016 | 1183 | 0.080 |
Why?
|
| Critical Illness | 1 | 2014 | 714 | 0.080 |
Why?
|
| Neoplasm Metastasis | 2 | 2017 | 5112 | 0.080 |
Why?
|
| Diet | 1 | 2016 | 1440 | 0.080 |
Why?
|
| Neuroendocrine Tumors | 1 | 2015 | 634 | 0.080 |
Why?
|
| Risk Assessment | 5 | 2021 | 6869 | 0.080 |
Why?
|
| Administration, Oral | 1 | 2012 | 1544 | 0.080 |
Why?
|
| Bone Cysts, Aneurysmal | 1 | 2008 | 21 | 0.080 |
Why?
|
| Myasthenia Gravis | 1 | 2009 | 99 | 0.080 |
Why?
|
| Blood Pressure | 3 | 2014 | 1467 | 0.080 |
Why?
|
| Heparin | 1 | 2010 | 360 | 0.080 |
Why?
|
| Blood Proteins | 1 | 2009 | 294 | 0.080 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 7222 | 0.080 |
Why?
|
| Oncogenes | 1 | 2011 | 673 | 0.080 |
Why?
|
| Vincristine | 1 | 2012 | 1511 | 0.080 |
Why?
|
| Lymphokines | 2 | 2016 | 272 | 0.080 |
Why?
|
| Texas | 1 | 2019 | 6311 | 0.080 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 1162 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 3 | 2022 | 2992 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2015 | 2508 | 0.080 |
Why?
|
| Ribs | 1 | 2008 | 91 | 0.080 |
Why?
|
| Thiazoles | 1 | 2012 | 726 | 0.080 |
Why?
|
| Blood Glucose | 1 | 2012 | 1244 | 0.080 |
Why?
|
| Bromodeoxyuridine | 1 | 2007 | 139 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2015 | 2203 | 0.070 |
Why?
|
| Dexamethasone | 1 | 2012 | 1450 | 0.070 |
Why?
|
| Cell Shape | 1 | 2007 | 128 | 0.070 |
Why?
|
| Stilbenes | 1 | 2007 | 86 | 0.070 |
Why?
|
| Papillomavirus Infections | 1 | 2015 | 980 | 0.070 |
Why?
|
| Structure-Activity Relationship | 1 | 2008 | 931 | 0.070 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2012 | 1094 | 0.070 |
Why?
|
| Pyridines | 2 | 2015 | 1244 | 0.070 |
Why?
|
| Erectile Dysfunction | 1 | 2008 | 212 | 0.070 |
Why?
|
| RNA Interference | 3 | 2015 | 1408 | 0.070 |
Why?
|
| Abdominal Injuries | 1 | 2007 | 80 | 0.070 |
Why?
|
| Cytochromes c | 1 | 2006 | 118 | 0.070 |
Why?
|
| Liver Cirrhosis | 1 | 2013 | 941 | 0.070 |
Why?
|
| Biomarkers | 3 | 2016 | 5047 | 0.070 |
Why?
|
| HeLa Cells | 3 | 2015 | 1643 | 0.070 |
Why?
|
| Microscopy, Fluorescence | 1 | 2008 | 769 | 0.070 |
Why?
|
| Quality of Health Care | 1 | 2020 | 621 | 0.070 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 1331 | 0.070 |
Why?
|
| rhoB GTP-Binding Protein | 1 | 2005 | 7 | 0.070 |
Why?
|
| Protein Biosynthesis | 2 | 1987 | 889 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 1265 | 0.070 |
Why?
|
| Serotonin | 1 | 1987 | 264 | 0.070 |
Why?
|
| Length of Stay | 3 | 2018 | 1900 | 0.070 |
Why?
|
| Hormone Antagonists | 1 | 2005 | 101 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2015 | 1062 | 0.070 |
Why?
|
| Deoxycytidine | 1 | 2011 | 1353 | 0.070 |
Why?
|
| Metabolomics | 1 | 2008 | 478 | 0.060 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2007 | 176 | 0.060 |
Why?
|
| Leupeptins | 2 | 2012 | 68 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2012 | 3001 | 0.060 |
Why?
|
| Mitosis | 3 | 2012 | 615 | 0.060 |
Why?
|
| Methionine | 1 | 2005 | 159 | 0.060 |
Why?
|
| Models, Biological | 2 | 2009 | 3254 | 0.060 |
Why?
|
| Gene Expression Profiling | 4 | 2022 | 5159 | 0.060 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2005 | 76 | 0.060 |
Why?
|
| Glucose | 1 | 2011 | 1248 | 0.060 |
Why?
|
| bcl-X Protein | 1 | 2005 | 196 | 0.060 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2006 | 334 | 0.060 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2015 | 1833 | 0.060 |
Why?
|
| Gene Expression | 3 | 2014 | 3570 | 0.060 |
Why?
|
| Cell Nucleus | 2 | 2010 | 1620 | 0.060 |
Why?
|
| Cell Division | 2 | 2015 | 2489 | 0.060 |
Why?
|
| Oxidation-Reduction | 1 | 2006 | 717 | 0.060 |
Why?
|
| Glutathione | 1 | 2006 | 368 | 0.060 |
Why?
|
| Antagomirs | 1 | 2023 | 19 | 0.060 |
Why?
|
| Protease Inhibitors | 2 | 2012 | 210 | 0.060 |
Why?
|
| Cell Cycle | 3 | 2015 | 2084 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 1054 | 0.060 |
Why?
|
| Piperidines | 1 | 2008 | 1035 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2022 | 4971 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2020 | 16273 | 0.060 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2005 | 430 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2023 | 84 | 0.050 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2008 | 600 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2017 | 1217 | 0.050 |
Why?
|
| Adaptive Immunity | 1 | 2023 | 149 | 0.050 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2023 | 243 | 0.050 |
Why?
|
| Zinc | 1 | 2003 | 188 | 0.050 |
Why?
|
| Cell Movement | 2 | 2018 | 2466 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2006 | 644 | 0.050 |
Why?
|
| Immunoprecipitation | 2 | 2015 | 591 | 0.050 |
Why?
|
| Lactates | 1 | 2021 | 112 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2017 | 1489 | 0.050 |
Why?
|
| Transcription, Genetic | 3 | 2015 | 3154 | 0.050 |
Why?
|
| Guideline Adherence | 2 | 2019 | 636 | 0.050 |
Why?
|
| Mice, Knockout | 1 | 2011 | 5710 | 0.050 |
Why?
|
| Protein Stability | 2 | 2012 | 370 | 0.050 |
Why?
|
| Flow Cytometry | 3 | 2015 | 3033 | 0.050 |
Why?
|
| Octreotide | 2 | 2015 | 118 | 0.050 |
Why?
|
| DNA Fragmentation | 1 | 2001 | 198 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2003 | 528 | 0.050 |
Why?
|
| Dextromethorphan | 1 | 2021 | 13 | 0.050 |
Why?
|
| Caspase 8 | 1 | 2001 | 145 | 0.050 |
Why?
|
| Survivorship | 1 | 2021 | 109 | 0.050 |
Why?
|
| Mutagenesis | 1 | 2003 | 483 | 0.050 |
Why?
|
| HT29 Cells | 1 | 2021 | 159 | 0.050 |
Why?
|
| Cytosol | 1 | 2001 | 238 | 0.050 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2023 | 249 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2007 | 1048 | 0.050 |
Why?
|
| Caspase 9 | 1 | 2001 | 189 | 0.050 |
Why?
|
| Drug Repositioning | 1 | 2021 | 54 | 0.050 |
Why?
|
| Child | 4 | 2020 | 29154 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2001 | 212 | 0.050 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2007 | 1299 | 0.050 |
Why?
|
| NIH 3T3 Cells | 2 | 2012 | 260 | 0.050 |
Why?
|
| Endothelial Growth Factors | 1 | 2001 | 197 | 0.050 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2014 | 413 | 0.050 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2012 | 2527 | 0.050 |
Why?
|
| Acupuncture Points | 1 | 2020 | 18 | 0.050 |
Why?
|
| Infusion Pumps | 1 | 2000 | 61 | 0.050 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2021 | 63 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 2594 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2015 | 3578 | 0.040 |
Why?
|
| Liver Transplantation | 1 | 2008 | 1112 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2006 | 1129 | 0.040 |
Why?
|
| DNA, Neoplasm | 1 | 2005 | 1910 | 0.040 |
Why?
|
| Phagocytosis | 1 | 2020 | 260 | 0.040 |
Why?
|
| Cell Line | 3 | 2012 | 5114 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2000 | 573 | 0.040 |
Why?
|
| Carcinogens | 1 | 2020 | 384 | 0.040 |
Why?
|
| Intracellular Space | 1 | 2019 | 77 | 0.040 |
Why?
|
| Ocular Physiological Phenomena | 2 | 1990 | 10 | 0.040 |
Why?
|
| Unnecessary Procedures | 1 | 2019 | 104 | 0.040 |
Why?
|
| Transforming Growth Factor alpha | 2 | 2012 | 95 | 0.040 |
Why?
|
| Nicotine | 1 | 2021 | 244 | 0.040 |
Why?
|
| Kininogens | 1 | 2018 | 8 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 4314 | 0.040 |
Why?
|
| Sorting Nexins | 1 | 2018 | 17 | 0.040 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 1 | 1 | 2018 | 29 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2020 | 490 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 10035 | 0.040 |
Why?
|
| Quality of Life | 2 | 2023 | 4532 | 0.040 |
Why?
|
| Enzyme Activation | 1 | 2001 | 1764 | 0.040 |
Why?
|
| Mitochondria | 1 | 2005 | 1282 | 0.040 |
Why?
|
| Piperazines | 1 | 2007 | 2101 | 0.040 |
Why?
|
| Vitamin D | 1 | 2000 | 261 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2015 | 3203 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 3639 | 0.040 |
Why?
|
| RNA | 1 | 2022 | 1013 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2005 | 1823 | 0.040 |
Why?
|
| Herpesvirus 8, Human | 1 | 2017 | 102 | 0.040 |
Why?
|
| Precipitin Tests | 1 | 1996 | 329 | 0.040 |
Why?
|
| Molecular Mimicry | 1 | 2016 | 72 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2001 | 891 | 0.040 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2009 | 208 | 0.040 |
Why?
|
| Down-Regulation | 2 | 2013 | 2074 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 833 | 0.040 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2022 | 1226 | 0.040 |
Why?
|
| Disease Management | 1 | 2022 | 1052 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2004 | 2295 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1996 | 568 | 0.030 |
Why?
|
| Vaccination | 1 | 2022 | 1123 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2022 | 1085 | 0.030 |
Why?
|
| China | 1 | 2017 | 606 | 0.030 |
Why?
|
| Mitotane | 1 | 2015 | 39 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2017 | 684 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 486 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2022 | 1506 | 0.030 |
Why?
|
| Organelle Biogenesis | 1 | 2015 | 32 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 166 | 0.030 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2016 | 157 | 0.030 |
Why?
|
| Disease Progression | 2 | 2017 | 6682 | 0.030 |
Why?
|
| Radiography | 1 | 2000 | 1904 | 0.030 |
Why?
|
| Subcellular Fractions | 2 | 2012 | 201 | 0.030 |
Why?
|
| Liver | 2 | 2013 | 2961 | 0.030 |
Why?
|
| Endoplasmic Reticulum | 1 | 1996 | 308 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2016 | 269 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2017 | 6150 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2017 | 1037 | 0.030 |
Why?
|
| SKP Cullin F-Box Protein Ligases | 1 | 2014 | 42 | 0.030 |
Why?
|
| Tachypnea | 1 | 2014 | 7 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 1382 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 1996 | 571 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2015 | 276 | 0.030 |
Why?
|
| Mass Spectrometry | 2 | 2010 | 702 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2016 | 318 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2015 | 280 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2015 | 660 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2007 | 3518 | 0.030 |
Why?
|
| Hypothermia | 1 | 2014 | 59 | 0.030 |
Why?
|
| Kinetics | 2 | 2015 | 2049 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2018 | 661 | 0.030 |
Why?
|
| Minocycline | 1 | 2005 | 182 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2015 | 1648 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 3343 | 0.030 |
Why?
|
| Cetuximab | 1 | 2015 | 472 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2016 | 621 | 0.030 |
Why?
|
| Diethylnitrosamine | 1 | 2013 | 36 | 0.030 |
Why?
|
| Cell Separation | 1 | 2015 | 612 | 0.030 |
Why?
|
| Glutamine | 1 | 2015 | 299 | 0.030 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 4 | 1 | 2013 | 27 | 0.030 |
Why?
|
| Calcium | 1 | 2000 | 1537 | 0.030 |
Why?
|
| Anilides | 1 | 2015 | 268 | 0.030 |
Why?
|
| Inpatients | 1 | 2018 | 678 | 0.030 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2016 | 494 | 0.030 |
Why?
|
| Antibodies | 1 | 1996 | 838 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2017 | 1021 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2019 | 1392 | 0.030 |
Why?
|
| Oximetry | 1 | 2014 | 172 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2017 | 2063 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 245 | 0.030 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2002 | 71 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 4892 | 0.030 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2012 | 83 | 0.030 |
Why?
|
| 3T3 Cells | 1 | 2013 | 355 | 0.030 |
Why?
|
| Algorithms | 2 | 2015 | 3890 | 0.030 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 2 | 2003 | 212 | 0.030 |
Why?
|
| Hypotension | 1 | 2014 | 210 | 0.030 |
Why?
|
| Interphase | 1 | 2012 | 145 | 0.030 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2013 | 195 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2017 | 1038 | 0.030 |
Why?
|
| Prosencephalon | 1 | 1991 | 43 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 4821 | 0.030 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 2012 | 122 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 1053 | 0.030 |
Why?
|
| Receptors, Opioid | 1 | 1991 | 35 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2012 | 64 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 1077 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 2139 | 0.030 |
Why?
|
| Protein Subunits | 1 | 2012 | 274 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 992 | 0.020 |
Why?
|
| Logistic Models | 1 | 2018 | 3441 | 0.020 |
Why?
|
| Fever | 1 | 2014 | 497 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2015 | 785 | 0.020 |
Why?
|
| Binding Sites | 1 | 2015 | 2171 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2013 | 351 | 0.020 |
Why?
|
| Rats | 2 | 2017 | 6086 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2021 | 2669 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2014 | 1546 | 0.020 |
Why?
|
| Neuregulin-1 | 1 | 2010 | 83 | 0.020 |
Why?
|
| Ubiquitin | 1 | 2012 | 344 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2018 | 1491 | 0.020 |
Why?
|
| Recurrence | 1 | 2019 | 4758 | 0.020 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2012 | 311 | 0.020 |
Why?
|
| Polyubiquitin | 1 | 2010 | 23 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2017 | 1320 | 0.020 |
Why?
|
| Adenoma | 1 | 2015 | 716 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2010 | 342 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 1991 | 321 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2012 | 842 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2022 | 8865 | 0.020 |
Why?
|
| Recoverin | 1 | 2009 | 22 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2010 | 231 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 2265 | 0.020 |
Why?
|
| Polyploidy | 1 | 2010 | 73 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2010 | 323 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2013 | 492 | 0.020 |
Why?
|
| G2 Phase | 1 | 2010 | 206 | 0.020 |
Why?
|
| Thymectomy | 1 | 2009 | 79 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2010 | 360 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 1487 | 0.020 |
Why?
|
| Light | 1 | 1990 | 245 | 0.020 |
Why?
|
| Causality | 1 | 2009 | 178 | 0.020 |
Why?
|
| Manubrium | 1 | 2008 | 1 | 0.020 |
Why?
|
| Cyclic AMP | 2 | 1987 | 358 | 0.020 |
Why?
|
| Thyroid Gland | 1 | 2011 | 355 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2017 | 1423 | 0.020 |
Why?
|
| Aneuploidy | 1 | 2010 | 369 | 0.020 |
Why?
|
| Stem Cells | 1 | 2015 | 1213 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 4298 | 0.020 |
Why?
|
| Eye Proteins | 1 | 1990 | 269 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2010 | 652 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2010 | 1008 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 1443 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2009 | 495 | 0.020 |
Why?
|
| Interleukin-18 | 1 | 2008 | 100 | 0.020 |
Why?
|
| Diuretics | 1 | 2008 | 170 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 756 | 0.020 |
Why?
|
| Age Distribution | 1 | 2009 | 698 | 0.020 |
Why?
|
| Age Factors | 1 | 2017 | 5377 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 866 | 0.020 |
Why?
|
| Colforsin | 1 | 1987 | 59 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 376 | 0.020 |
Why?
|
| DNA Repair | 1 | 2015 | 1872 | 0.020 |
Why?
|
| Rupture | 1 | 2007 | 61 | 0.020 |
Why?
|
| Health Surveys | 1 | 2008 | 402 | 0.020 |
Why?
|
| Reference Values | 1 | 2009 | 1099 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 4233 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 3719 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2008 | 310 | 0.020 |
Why?
|
| Antidepressive Agents | 1 | 2008 | 332 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 6942 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2016 | 4078 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2009 | 1869 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 2330 | 0.020 |
Why?
|
| Eye | 1 | 1987 | 301 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 3101 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2008 | 615 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2008 | 938 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2007 | 1618 | 0.010 |
Why?
|
| Quercetin | 1 | 2003 | 16 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2009 | 2316 | 0.010 |
Why?
|
| Action Potentials | 1 | 1987 | 560 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 2008 | 889 | 0.010 |
Why?
|
| Databases, Protein | 1 | 2003 | 100 | 0.010 |
Why?
|
| Epidermal Growth Factor | 1 | 2004 | 423 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2003 | 448 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2008 | 915 | 0.010 |
Why?
|
| Comorbidity | 1 | 2009 | 2352 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2007 | 1665 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 2927 | 0.010 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2003 | 324 | 0.010 |
Why?
|
| Benzamides | 1 | 2007 | 1832 | 0.010 |
Why?
|
| Carcinoma, Papillary | 1 | 2004 | 584 | 0.010 |
Why?
|
| Anisomycin | 2 | 1990 | 11 | 0.010 |
Why?
|
| Mesothelioma | 1 | 2002 | 544 | 0.010 |
Why?
|
| Proteomics | 1 | 2003 | 1380 | 0.010 |
Why?
|
| Guanylyl Imidodiphosphate | 1 | 1991 | 7 | 0.010 |
Why?
|
| Enkephalins | 1 | 1991 | 23 | 0.010 |
Why?
|
| Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 1 | 1991 | 33 | 0.010 |
Why?
|
| Cell Fractionation | 1 | 1991 | 68 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1991 | 410 | 0.010 |
Why?
|
| Receptors, Opioid, mu | 1 | 1991 | 86 | 0.010 |
Why?
|
| Cycloheximide | 1 | 1990 | 97 | 0.010 |
Why?
|
| Cyclic GMP | 1 | 1990 | 116 | 0.010 |
Why?
|
| Potassium | 1 | 1990 | 329 | 0.010 |
Why?
|
| Leucine | 1 | 1990 | 352 | 0.000 |
Why?
|
| Cell Membrane | 1 | 1991 | 850 | 0.000 |
Why?
|
| Animals, Newborn | 1 | 1991 | 1338 | 0.000 |
Why?
|
| Amino Acids | 1 | 1990 | 728 | 0.000 |
Why?
|
| Bucladesine | 1 | 1984 | 31 | 0.000 |
Why?
|
| Aging | 1 | 1991 | 1582 | 0.000 |
Why?
|